Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Malcolm K. Brenner, M.D., Ph.D.

Malcolm K. Brenner, M.D., Ph.D.

Malcolm K. Brenner, M.D., M.B., Ph.D.,

Malcolm K. Brenner, M.D., Ph.D.

Senior Affiliate Member
The Methodist Hospital Research Institute
Fayez S. Sarofim Chair and Director, Center for Cell and Gene Therapy
Professor of Medicine and Pediatrics
Baylor College of Medicine

Phone: 832-824-4671
Fax: 832-825-4668
E-mail: mbrenner@bcm.tmc.edu


B.A.   Cambridge University, England (Medical Sciences and Pathology)
M.D.   Westminster Medical School, London, England
Ph.D.   Cambridge University, England

Postdoctoral Training

Fellowship, Department of Medicine, Royal College of Physicians, London, England
Fellowship, Department of Haematology, Royal College of Pathologists, London, England
Medical Research Council Training Fellowship, Division of Immunology, Department of Pathology, Cambridge University, England



Dr. Brenner completed his postdoctoral training in 1981 and joined the Clinical Research Centre of Northwick Park Hospital in London, England as a MRC Clinical Scientist and Honorary Senior Registrar. He also began lecturing in Haematology at the Royal Free Hospital and Hospital for Sick Children, also in London.

Dr. Brenner joined the faculty at the University of Tennessee in Memphis as a Professor in the Departments of Pediatrics and Medicine in 1990. He also became the Director of the Bone Marrow Transplant Division of the St. Jude Children's Research Hospital that same year. He later directed the Cell and Gene Therapy Program at St. Jude's from 1994 until 1997, when he assumed his current positions at the Baylor College of Medicine.


Description of Research

Dr. Brenner's research focuses on gene transfer to stem cells and to effector cells of the immune system. His research group was one of the first to use gene transfer in human subjects, establishing the feasibility of tracking human stem cells and their progeny in subjects with cancer. Dr. Brenner also develops tumor vaccines for pediatric and hematological malignancies, using genetic modification with retroviral and adenoviral vectors.


Major Areas of Research

Cell therapy, gene therapy, stem cells, vectors.


Recent Publications

Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 May 14

Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B. T lymphocytes co-expressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and anti-tumor activity in a Hodgkin's tumor model. Blood. 2009 Apr 17

Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May;17(5):880-8. Epub 2009 Mar 3.

Louis CU, Brenner MK. Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics. Curr Pharm Des. 2009;15(4):424-9.

Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov;14(11):1264-70. Epub 2008 Nov 2.